LncRNA NONRATT021972 in Neuropathic Pain Patients with Type 2 Diabetes

Abstract

Objective to explore LncRNA NONRATT021972 in diabetic neuropathic pain and detailed mechanisms in clinical patient. Methods According to inclusion criteria, 154 Chinese patients with type 2 diabetes were enrolled as experimental group, and the same numbers of normal adults were paired as control group with the same baseline status. Patients without diabetes but neuropathy were also enrolled to explore exclusive role of LncRNA NONRATT021972 in neuropathy. Vein blood sampling was performed in both groups for further experiment. Quantitative Real-time PCR was performed to examine expression of LncRNA NONRATT021972 in blood. Neuropathic pain scores were calculated with data collected from Neuropathic Pain Questionnaire in Both groups. Result Compared with control group, patients with type 2 diabetes had a significantly higher concentration of LncRNA NONRATT021972 in blood (P<0.05) and more severe symptoms of neuropathic pain. Moreover, among patients with type 2 diabetes, the concentration of LncRNA NONRATT021972 was positively associated with neuropathic pain scores, suggesting pain-aggravation effect of LncRNA NONRATT021972 was concentration-dependent. However, no association was observed between neuropathy and LncRNA NONRATT021972 in patients without diabetes but neuropathy. Conclusion LncRNA NONRATT021972 was increased in type 2 diabetes, and was positively associated with neuropathic pain scoring in patients with type 2 diabetes.